Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Anitocabtagene autoleucel (anito-cel) clinical trial manufacturing experience in patients with relapsed/refractory (RR) or newly diagnosed (ND) multiple myeloma (MM).

Krina K. Patel, Clare Spooner, Monique Giordana et al. Jun 01, 2026 pp. 2550-2550 10.1200/jco.2026.44.16_suppl.2550

2550 Background: Anito-cel is an autologous D-Domain–based anti-BCMA chimeric antigen receptor (CAR) T-cell therapy that d...

Impact of niraparib maintenance on progression-free survival and overall survival: An updated meta-analysis.

Roshan Mustafa Pathan, Jugraj Singh, Ponni Gayatri Twinkle Bade et al. Jun 01, 2026 pp. 5591-5591 10.1200/jco.2026.44.16_suppl.5591

5591 Background: Niraparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor used as maintenance therapy in advanced...

LIF expression as a predictive biomarker in metastatic renal cell carcinoma.

Mustafa Saleh, Eddy Saad, Marc Machaalani et al. Jun 01, 2026 pp. 4548-4548 10.1200/jco.2026.44.16_suppl.4548

4548 Background: Clear cell renal cell carcinoma (ccRCC) is biologically heterogeneous, and optimal selection between VEGF...

FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non–small cell lung cancer.

Hamid Emamekhoo, Salman Rafi Punekar, Theodore Stewart Gourdin et al. Jun 01, 2026 pp. 8560-8560 10.1200/jco.2026.44.16_suppl.8560

8560 Background: FF-10832, a stable liposomal formulation of gemcitabine with a prolonged half-life (mean t...

Multidisciplinary AE management education for EGFR-mutated NSCLC: Mixed-methods QI outcomes.

Michael White, Tariqa Ackbarali, Jason Olivieri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23368

e23368 Background: Anti-EGFR therapies for EGFR-mutated NSCLC have dermatologic and other adverse events (AEs) that benefi...

Effects of immune checkpoint inhibitor on the quality of life of patients with advanced/metastatic esophageal, gastro-esophageal junction, and gastric cancers: A systematic review of randomized controlled trials.

Akhil Deepak Vatvani, Gilbert Lazarus, Rama Nada et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16351

e16351 Background: Immune checkpoint inhibitors (ICIs) have demonstrated survival benefits in patients with advanced or me...

Phase 1b dose-expansion study of IMC-002, a anti-CD47 monoclonal antibody, in patients with advanced triple negative breast cancer (TNBC).

Ji Hyung Hong, Keun Seok Lee, Sung Hoon Sim et al. Jun 01, 2026 pp. 2524-2524 10.1200/jco.2026.44.16_suppl.2524

2524 Background: IMC-002 is a novel therapeutic agent with a distinct mechanism of action. In a phase 1a dose-escalation s...

GDF-15 in oropharyngeal squamous cell carcinoma (OPSCC): Association of an HPV-dependent biomarker with malnutrition and low skeletal muscle.

Lorena Arribas, Sara Tous, Maryam Choulli et al. Jun 01, 2026 pp. 6110-6110 10.1200/jco.2026.44.16_suppl.6110

6110 Background: GDF15 is a stress-response cytokine implicated in systemic inflammation and cancer-related wasting. We as...

Impact of SGLT2 inhibitors on clinical outcomes in diabetic patients with CLL receiving BTK inhibitors: A global propensity-matched study.

Angimar Uriepero-Palma, Dhriti Sood, Muluken Megiso et al. Jun 01, 2026 pp. 7051-7051 10.1200/jco.2026.44.16_suppl.7051

7051 Background: Diabetic patients with chronic lymphocytic leukemia (CLL) receiving Bruton’s tyrosine kinase inhibitors (...

Prospective analysis of cardiovascular complications in HER2-positive breast cancer patients treated with anthracycline-free regimens.

Aminat Khamzatkhanova, Elena Shavarova, Maria Poltavskaya et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12545

e12545 Background: The assessment of cardiovascular complications (CVC) frequency and the predictive role of the HFA-ICOS...

ILCness to stratify lobular-like breast cancer biology and as an outcome independent of <i>CDH1</i> mutation in early ER-positive/HER2-negative breast cancer.

Masanori Oshi, Sasagu Kurozumi, Mayu Hizume et al. Jun 01, 2026 pp. 576-576 10.1200/jco.2026.44.16_suppl.576

576 Background: Invasive lobular carcinoma (ILC) represents a distinct histological subtype of breast cancer; however, its...

Real-world utilization and outcomes of hematopoietic stem cell transplantation in testicular cancer.

Raj N. Shah, Deevyashali Parekh, Fady El Tom et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17016

e17016 Background: Approximately 10–30% of patients with testicular cancer experience relapse or develop platinum-refracto...

Survival outcomes with contemporary treatments including immunotherapy for poorly differentiated neuroendocrine carcinomas of the head and neck.

Rushabh Gujarathi, Shreyas Kalantri, Rebecca A. Redman Jun 01, 2026 pp. 6115-6115 10.1200/jco.2026.44.16_suppl.6115

6115 Background: Poorly differentiated Neuroendocrine Carcinomas of the Head and Neck (HN-NECs) are rare aggressive malign...

Mortality from pulmonary embolism among patients with lung and bronchus malignancies: National trends and forecasting from CDC WONDER (1999–2030).

Diljot Singh, Arbaz Hassan, Wishad Waris et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20116

e20116 Background: Pulmonary embolism (PE) represents a major cause of preventable mortality in patients with lung cancer...

Attenuation of long-term survival benefit of biological therapy in metastatic colorectal cancer (mCRC): Real-world data validation and molecular characterization.

Sanjay Goel, Yasmine Baca, Joanne Xiu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15589

e15589 Background: Incorporation of biologic drugs to chemo has improved overall survival (OS) of patients with metastatic...

Can robotic surgery better preserve sensory function?: The significance and strategy of nerve preservation in axillary lymph node dissection.

Qiwen Liu, Zongyan Li, Yueyue Teng et al. Jun 01, 2026 pp. 582-582 10.1200/jco.2026.44.16_suppl.582

582 Background: Conventional axillary lymph node dissection (C-ALND) carries a high risk of damaging the intercostobrachia...

Driving efficiency in oncology care: Tactical solutions for inpatient flow challenges.

Catherine Delanoix, Kaycee Wilson, Corey Russell et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13566

e13566 Background: Hospital compression limits access to timely care with a negative impact on patients. These pressures h...

Neoadjuvant camrelizumab with chemotherapy (NACI) in PD-L1-negative locally advanced cervical cancer: An open-label, multi-center, single-arm, phase 2 trial.

Yingjie Hu, Jie Yang, Jing Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17510

e17510 Background: Locally advanced cervical cancer (LACC) remains associated with suboptimal outcomes with conventional t...

Clinically actionable TURBT-derived bladder cancer organoid pharmacotyping as a predictor of postoperative outcomes in a prospective multicenter study.

Yihao Zhao, Shijie Zhang, Xiaoyi Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16613

e16613 Background: Post-TURBT chemotherapy is largely empiric despite marked inter-patient heterogeneity in bladder cancer...

Clinical outcomes of muscle-invasive and metastatic, bladder, and urethral pure adenocarcinoma (BUAdenoCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).

Brooke Elizabeth Kania, Liliana Ascione, Roger Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16565

e16565 Background: BUAdenoCa are rare and their management options are limited. The GSRGT assembled an international cohor...

Does surgery improve breast cancer–specific survival in low-grade DCIS?: A 20-year population-based analysis by nuclear grade.

Fatih Aydogan, Ahmet Necati Sanli, Deniz Esin Tekcan Sanli et al. Jun 01, 2026 pp. 578-578 10.1200/jco.2026.44.16_suppl.578

578 Background: Active surveillance is increasingly discussed for low-risk ductal carcinoma in situ (DCIS), yet randomized...

Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819.

Kai Zhang, Pushkar Mutha, Omid Haji Maghsoudi et al. Jun 01, 2026 pp. 8549-8549 10.1200/jco.2026.44.16_suppl.8549

8549 Background: Despite two decades of anti-angiogenic therapy in NSCLC, no predictive biomarker identifies which patient...

Osimertinib combined with bevacizumab and chemotherapy as 1L treatment in EGFR-mutated metastatic non-squamous non-small cell lung cancer (nsq NSCLC) with concurrent mutations.

Liang Liu, Yanjuan Xiong, Yang Wang et al. Jun 01, 2026 pp. 8625-8625 10.1200/jco.2026.44.16_suppl.8625

8625 Background: Concurrent mutations in EGFR sensitive mutations (19 del/21 L858R) are associated with poor prognosis. Pr...

Epidemiological trends and burden of pancreatic cancer in the United States: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.

Anika Chowdhury, Ibrahim Khalil, Sunjida Amin Promi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16402

e16402 Background: Pancreatic cancer remains a leading cause of cancer-related burden in the United States, with persisten...

Clinical impact of R0 resection after chemotherapy in initially unresectable metastatic colorectal cancer: A pooled analysis of the ARCAD database.

Koji Ando, Toshihiro Misumi, Hideaki Bando et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15557

e15557 Background: In metastatic colorectal cancer (mCRC), systemic chemotherapy can enable conversion surgery in a subset...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page